- Home
- CMMB vs ACCS Comparison
CMMB vs ACCS Comparison
Compare CMMB & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | ACCS |
|---|---|---|
| Founded | 2004 | 1988 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 19.1M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CMMB | ACCS |
|---|---|---|
| Price | $1.31 | $4.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $15.00 | $12.50 |
| AVG Volume (30 Days) | ★ 117.2K | 22.4K |
| Earning Date | 11-19-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 101.67 | ★ 139.36 |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $22,619,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.82 |
| P/E Ratio | $40.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.35 | $4.70 |
| 52 Week High | $3.55 | $11.34 |
Technical Indicators
Market Signals| Indicator | CMMB | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 25.39 | 39.38 |
| Support Level | N/A | N/A |
| Resistance Level | $1.83 | $5.23 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 13.07 | 2.83 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.